Obalon Balloon System Data to be Featured in Presentation During 35th ASMBS Annual Meeting at Obesity Week 2018
November 07 2018 - 9:15AM
Clinical results from over 1,300 patients at 108 sites
treated with Obalon’s novel weight loss device solution in
commercial use
Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated
medical technology company with the first and only FDA-approved
swallowable, gas-filled intragastric balloon system for the
treatment of obesity, announces that clinical data for the
Obalon Balloon System in commercial use in over 1,300 patients at
108 sites will be featured in an oral presentation at the American
Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting
at Obesity Week 2018, being held November 11-15, 2018 in Nashville,
TN. The data will be presented by Dr. Rachel Moore on November 14,
2018 at 5:00 pm (details below). Obalon believes this to be
largest, single, consecutive data set ever presented on the
commercial use of an intragastric balloon.
“We believe we have a novel, differentiated solution for weight
loss that is performing as intended in actual commercial practice,”
said Amy VandenBerg, Vice President of Clinical and Regulatory
Affairs. “We are pleased to have data on the Obalon Balloon
presented by Dr. Moore in a scientific forum at the largest medical
meeting focused on obesity and believe the results validate the
potential of the Obalon Balloon to impact the obesity
epidemic.”
Details for the ASMBS oral presentation are as
follows:
Title: The First Six Months of Commercial
Experience with a Swallowable Gas-filled Three Balloon System
Results in Safe and Clinically Meaningful Weight Loss
(206764)Session Title: Scientific
SessionDate and Time: Wednesday, November 14,
2018, 5:05 p.m. - 5:15 p.m. CDTLocation: Music
City Center
About Obalon Therapeutics, Inc. Obalon
Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company
focused on developing and commercializing novel technologies for
weight loss. The Obalon management team has over 150 combined years
of experience in developing and commercializing novel medical
technologies with a track record of financial and clinical
excellence. For more information, please
visit www.obalon.com.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Obalon
Therapeutics, they are forward-looking statements reflecting the
current beliefs and expectations of management made pursuant to the
safe harbor of the Private Securities Reform Act of 1995. Such
forward-looking statements involve substantial risks and
uncertainties that could cause Obalon Therapeutics' future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties inherent
in the product research, development and regulatory process and
risks. Obalon Therapeutics undertakes no obligation to update or
revise any forward-looking statements. For a further description of
the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Obalon Therapeutics' business in general,
please refer to Obalon Therapeutics’ quarterly report on Form 10-Q
filed with the Securities and Exchange Commission on November 2,
2018, and its current and future periodic reports filed with the
Securities and Exchange Commission.
For Obalon Therapeutics, Inc.
Investor Contact: William Plovanic Chief Financial Officer
Obalon Therapeutics, Inc. Office: +1 760 607 5103
wplovanic@obalon.com
Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220
mdriscoll@evolvemkd.com
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Apr 2023 to Apr 2024